Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ozuriftamab vedotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ozuriftamab vedotin overview
BA-3021 is under development for the treatment of solid tumors include unresectable or metastatic, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), melanoma, metastatic melanoma, pancreatic cancer, colorectal cancer, rectal carcinoid tumor, head and neck cancer, soft tissue sarcoma (STS), ovarian cancer, fallopian tube cancer, peritoneal cancer, recurrent or metastatic squamous cell carcinoma of the head and neck, oropharynx, oral cavity, hypopharynx, and larynx cancer. The drug candidate acts by targeting tyrosine-protein kinase transmembrane receptor (ROR2). It is developed based on conditionally active biologics (CAB) platform. It is administered through intravenous route.
BioAtla overview
BioAtla is a biotech company that develops novel monoclonal antibody and cell-based therapeutics using proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms. The company’s pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, squamous cell carcinoma of the head and neck; BA3182 treat adenocarcinomas; BA3361 for multiple tumor types; and BA3071 (Evalstotug) treat melanoma, non-small cell lung cancer (NSCLC) and carcinomas. BioAtla is headquartered in San Diego, California, the US.
For a complete picture of Ozuriftamab vedotin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
